The decision to pursue this integration process was made following ICRC-Weyer’s recent participation at the Evolution Summit in Munich, Germany, an industry forum bringing together representatives from the pharmaceutical and biotech industries with innovative solution providers. At the event, Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer, presented her findings and experiences in striking a balanced medical review process to build a robust Pharmacovigilance strategy.
‘The talk generated a tremendous amount of interest in the topic and resulted in positive feedback and interesting discussions with delegates’ says Dr Treichel. ‘We were particularly pleased about specific requests that were made by trial sponsors at the event. Our Pharmacovigilance and Medical Review teams are very happy to provide this special service and therefore meet the growing demand of pharmaceutical and biotech companies.’
Most Pharmacovigilance systems suffer either from a complete lack of medical review integration or, at the other extreme, a single all-inclusive process resulting in over-integration. By adapting a balanced medical review process ICRC-Weyer is able to build a robust Pharmacovigilance strategy.
Dr Treichel’s talk featured several aspects of this topic, including the assessment of current risk management approaches to pinpoint drawbacks and improve Pharmacovigilance strategies, the identification of expected benefits, potential difficulties and practical considerations of medical review for effective integration, examining past case studies to uncover unforeseen threats and debunk false risks as well as improving processes and minimising overall risks through the successful execution of integrated medical review.
